DENALI THERAPEUTICS INC. (DNLI)

(10% Negative) DENALI THERAPEUTICS INC. (DNLI) Announces Delay in approval Trials for AVLAYAH™ (tividenofusp alfa-eknm) Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment